Overview
Although there is limited evidence supporting the effectiveness of current treatments, there are a number of promising new drugs in the pipeline. In addition to the existing treatments, some of these therapies are still being developed and evaluated in clinical trials. Non-invasive ventilation and nitrates are the mainstays of pulmonary edema therapy. Diuretics are used in higher doses, but are associated with transient declines in renal function. The best treatment for pulmonary edema involves using herbal remedies. They are considered effective and are not harmful to the body. The herbal medicines used are known to improve oxygenation and reduce extracellular fluid. The most effective treatment involves using nitrates, diuretics, and nitrates. In the case of acute pulmonary edema, the drug used should be prescribed by a doctor.
Competitive Landscape
Major companies contributing to the global pulmonary edema therapeutics market include Amgen Inc., Cytokinetics Inc., Novartis International AG, United Therapeutics Corporation, Celularity Inc., and AstraZeneca plc.
Buy-Now This Report and get UPTO 80% DISCOUNT
Purchase This Premium Report With Discounted Rate @ https://www.coherentmarketinsights.com/insight/buy-now/4493
Drivers
The increasing prevalence of congestive cardiovascular diseases and strokes among the senescent population is expected to propel the growth of the pulmonary edema therapeutics market during the forecast period.
Moreover, the growing number of diuretic and morphine therapeutics to diagnose cardiovascular conditions is expected to boost the growth of the pulmonary edema therapeutics market over the forecast period.
Summary of the COVID-19 Debacle
The global pulmonary edema therapeutics market has responded positively to the prevalence of the COVID-19 pandemic. These therapeutics were widely used in critical COVID patients as they were found to mitigate chronic damage to the heart. With the emergence of new C-19 variants, the market seems to have a long road ahead for expansion.
Key Takeaways
- The pulmonary edema therapeutics market is anticipated to grow at a CAGR of 6.9 % during the forecast period owing to the increasing research and development activities to develop efficient therapeutics amidst growing cases of cardiovascular diseases. For instance, in November 2021, the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) by Merck, making it the first-ever immunotherapy approved for RCC (renal cell carcinoma) patients.
- Across the geographical horizons, the North American region is estimated to emerge as a clear leader in the global pulmonary edema therapeutics market on the heels of growing drug approvals and increasing cases of congestive cardiovascular disorders.
- Coming in at number two this timeframe should be the Asia Pacific region, which is augmenting the global pulmonary edema therapeutics market on account of high demand from the pharmaceutical sector, a large caseload of cardiovascular diseases, and increasing awareness over bleeding diseases.
Table of Content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Pulmonary Edema Therapeutics Market Size Analysis from 2021 to 2028
11.6 COVID-19 Outbreak: Pulmonary Edema Therapeutics Industry Impact
Chapter 2 Global Pulmonary Edema Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Pulmonary Edema Therapeutics (Volume and Value) by Type
2.3 Global Pulmonary Edema Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Pulmonary Edema Therapeutics Sales, Consumption, Export, Import by Regions (2016-2021)
Chapter 5 North America Pulmonary Edema Therapeutics Market Analysis
Chapter 6 East Asia Pulmonary Edema Therapeutics Market Analysis
Chapter 7 Europe Pulmonary Edema Therapeutics Market Analysis
Chapter 8 South Asia Pulmonary Edema Therapeutics Market Analysis
Chapter 9 Southeast Asia Pulmonary Edema Therapeutics Market Analysis
Chapter 10 Middle East Pulmonary Edema Therapeutics Market Analysis
Chapter 11 Africa Pulmonary Edema Therapeutics Market Analysis
Chapter 12 Oceania Pulmonary Edema Therapeutics Market Analysis
Chapter 13 South America Pulmonary Edema Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Pulmonary Edema Therapeutics Business
Chapter 15 Global Pulmonary Edema Therapeutics Market Forecast (2021-2027)
Chapter 16 Conclusions
Research Methodology
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837